A new academic enterprise, born of a partnership between the University of Washington and China’s Tsinghua University — and seeded with $40 million in funding from Microsoft — welcomed its first class of master’s students this fall.
Gene therapy is at the forefront of preventative and therapeutic technologies targeting diseases that have no other cures. Join us as two leading gene therapy experts, Drs. Karen Kozarsky and Lynne Fahey McGrath, discuss different types of gene therapy, advanced programs, and the associated unique regulatory challenges.
Rhythm Pharmaceuticals $RYTM became the latest biotech to tap into a buoyant market, raising $120 million in an IPO that went over the range at $17 a share. And they can add substantially to that if the underwriters pick up another million shares on the table.
We know from following the Rise of the Rest that D.C. isn’t in the top three for metros venture capital investments, but a new study said it makes the top 10.
The Center for Innovative Technology (CIT) announced today the Commonwealth Research Commercialization Fund (CRCF) Request for Proposals (RFP) for FY2018.
TEDCO, the Maryland Technology Development Corporation, awarded four recipients more than $1 million for stem cell research for validation and commercialization of products. LifeSprout and RoosterBio received awards totaling $600,000 to help commercialize products based on stem cell technology.
Johns Hopkins Tech Ventures is expanding its entrepreneurship and incubation services for university students.
What happens to startups when they’ve outgrown coworking, but aren’t ready a whole office suite? There’s an incubator for that.
Accelspace is #dctech’s latest incubator, aimed at high-growth, mid-level, startups. Currently the incubator has offices in downtown D.C. and Crystal City.
The University of Maryland will receive a $219.5 million donation from the A. James and Alice B. Clark Foundation created by the late contracting titan James Clark.
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract valued at up to approximately $25 million by the U.S. Department of State to supply TROBIGARD™ (Atropine Sulfate [2mg]/Obidoxime Chloride [220mg]) auto-injector, a drug and device combination product for emergency use in the event of nerve agent or organophosphate poisoning. Trobigard is designed for intramuscular self- or buddy-administration of atropine sulfate and obidoxime chloride for pre-hospital intervention.
